There are myriad studies which find very little difference in treatment effectiveness between Eylea and Lucentis, therefore it is likely that COAST & SHORE trials would produce similar results. That said Eylea has a an advantage in durability. If the phase 3 repeats previous results and demonstrates an approximate 30% improvement in visual acuity, then OPT is going to have a very popular drug in combination with either existing treatment.
There are myriad studies which find very little difference in...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
-0.005(1.20%) |
Mkt cap ! $504.7M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 40.8¢ | $499.8K | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24187 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 20978 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |